News | Stents Drug Eluting | June 03, 2016

ORIENT Trial Results on Orsiro Hybrid Drug-Eluting Stent Presented at EuroPCR 2016

Data establish Orsiro's non-inferiority to Resolute Integrity Stent; STEMI subgroup from BIOSCIENCE trial has 50 Percent lower target lesion failure rate versus Xience

Biotronik, ORIENT trial results, EuroPCR 2016, Orsiro DES, hybrid drug-eluting stent

June 3, 2016 — Biotronik announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Resolute Integrity DES were presented during a Hotline Session at EuroPCR 2016. The multicenter, randomized, controlled all-comers ORIENT trial enrolled 372 patients who received either Orsiro or Resolute Integrity in treatment of a wide variety of coronary heart disease.

“Orsiro’s refined design, including a biodegradable polymer and ultrathin struts, improve patient safety and angiographic outcomes,” commented ORIENT trial principal investigator Tae-Jin Youn, M.D., Seoul National University Bundang Hospital, South Korea. “In this trial, Orsiro conclusively demonstrated non-inferiority to the competitor DES in terms of in-stent late lumen loss.”

The ORIENT trial’s primary endpoint was in-stent late lumen loss (LLL) at nine months, an angiographic endpoint. Orsiro demonstrated significant non-inferiority for the primary end point — at nine months the trial’s Orsiro arm had an average LLL of 0.10 ± 0.35, while patients in the Resolute Integrity arm had an LLL of 0.16 ± 0.39 (P for non-inferiority=<0.001). The trial furthermore highlighted Orsiro’s excellent safety profile, with no stent thrombosis observed.

At EuroPCR 2016, positive 24 months results for ST-segment elevation myocardial infarction (STEMI) patients were also presented as part of the official program and during a scientific symposium on Orsiro. STEMI is a potentially fatal type of heart attack caused by a prolonged obstruction of blood supply in the heart. Every year nearly 250,000 people experience STEMI heart attacks. A subanalysis of 407 STEMI patients was included in the multicenter, randomized, controlled non-inferiority BIOSCIENCE trial. Results from the trial have been published in The Lancet and EuroIntervention; these had already revealed that Orsiro might be associated with better clinical outcomes than Xience Prime/Xpedition for this indication.

At two years, BIOSCIENCE’s primary endpoint of target lesion failure (TLF) occurred in 5.4 percent of STEMI patients treated with Orsiro compared with 10.8 percent of those treated with Xience Prime/Xpedition. BIOSCIENCE is the largest investigator-initiated study to date evaluating the safety and efficacy of Orsiro, a bioabsorbable polymer DES, in comparison to the durable polymer Xience Prime/Xpedition DES.

The Orsiro Hybrid Drug-Eluting Stent (DES), launched in 2011, combines passive and active components. proBIO passive coating encapsulates the stent and minimizes interaction between the metal stent and the surrounding tissue. BIOlute active coating contains a highly biocompatible polymer that delivers a limus drug via a bioabsorbable matrix. This hybrid coating is layered on top of the high performance PRO-Kinetic Energy stent platform, renowned for its advanced ultrathin-strut stent design and outstanding deliverability.

For more information: www.biotronik.com

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th